Table of Contents

1 Introduction

    1.1 Objectives of the Study 

    1.2 Market Definition 

    1.3 Market Scope 

           1.3.1 Markets Covered

           1.3.2 Years Considered for the Study

    1.4 Currency 

    1.5 Limitations 

    1.6 Stakeholders

2 Research Methodology

    2.1 Research Methodology 

    2.2 Secondary and Primary Research Methodology 

           2.2.1 Secondary Research

                    2.2.1.1 Key Data From Secondary Sources

           2.2.2 Primary Research

                    2.2.2.1 Key Data From Primary Sources

                    2.2.2.2 Key Insights From Primary Sources

                    2.2.2.3 Key Industry Insights

    2.3 Market Size Estimation Methodology 

    2.4 Market Forecast Methodology 

    2.5 Market Data Validation and Triangulation 

    2.6 Assumptions for the Study

3 Executive Summary

    3.1 Introduction 

    3.2 Conclusion

4 Premium Insights

    4.1 Humanized Mouse Model Market:  Overview 

    4.2 Regional Analysis: Global Market, By End User 

    4.3 Global Market, By Application, 2016 vs 2021 

    4.4 Regional Snapshot: Global Market

5 Market Overview

    5.1 Introduction 

    5.2 Market Dynamics 

           5.2.1 Drivers

                    5.2.1.1 Surge in Research Activities Involving Humanized Mouse Models

                               5.2.1.1.1 Mouse Models for Immunodeficiency Disorders

                               5.2.1.1.2 Mouse Models for Cancer

                               5.2.1.1.3 Mouse Models for Rare Diseases

                    5.2.1.2 Growing Adoption of Personalized Medicine to Fuel the Demand for Personalized Mouse Models

                    5.2.1.3 Continuous Support in the Form of Investments and Grants From the Government and Private Sectors

                               5.2.1.3.1 Funding/Grants By the National Institutes of Health (NIH)

                               5.2.1.3.2 Funding/Grants Received From Other Government Bodies

                    5.2.1.4 Increase in R&D Activities Carried Out By Pharmaceutical and Biotechnology Companies

           5.2.2 Restraints

                    5.2.2.1 Regulations and Laws Formulated for Ethical Use of Animals

                               5.2.2.1.1 The Animal Welfare Act (AWA)

                               5.2.2.1.2 Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals

                    5.2.2.2 Increased Use of Rat Models

           5.2.3 Opportunities

                    5.2.3.1 Increased Production of Monoclonal Antibodies

           5.2.4 Challenges

                    5.2.4.1 Advances in Zebrafish Model Development

                    5.2.4.2 Alternatives to Animal Testing

                    5.2.4.3 Limitations of Humanized Mouse Models

6 Clinical Trials and Research Studies Assessment

    6.1 Introduction 

    6.2 Clinical Trials 

    6.3 Research Studies

7 Humanized Mouse Model Market, By Type

    7.1 Introduction 

    7.2 Genetic Humanized Mouse Model 

    7.3 Cell-Based Humanized Mouse Model 

           7.3.1 CD34 Humanized Mouse Model (Hu-CD34)

           7.3.2 PBMC Humanized Mouse Model

           7.3.3 BLT Humanized Mouse Model

8 Humanized Mouse Model Market, By Application

    8.1 Introduction 

    8.2 Oncology 

           8.2.1 Agreements/Collaborations to Strengthen Cancer Research

           8.2.2 Continuous Grants/Funds to Support Cancer Research Studies

    8.3 Immunology and Infectious Diseases 

    8.4 Neurosciences 

           8.4.1 Grants/Funds for Neurological Research

    8.5 Toxicology 

    8.6 Hematopoiesis 

    8.7 Other Applications 

           8.7.1 Increasing Funding for Rare Disease Research

9 Humanized Mouse Model Market, By End User

    9.1 Introduction 

    9.2 Pharmaceutical and Biotechnology Companies 

    9.3 Contract Research Organizations 

    9.4 Academic and Research Institutions

10 Global Humanized Mouse Model Market, By Region (Page No. - 85)

     10.1 Introduction 

     10.2 North America 

             10.2.1 U.S.

                        10.2.1.1 Availability of Support for Research in the U.S.

                        10.2.1.2 Preclinical Activities By Cros and Pharmaceutical R&D

                        10.2.1.3 Conferences and Other Events Contributing to the Spread of Innovation and Awareness

                        10.2.1.4 Growing Monoclonal Antibody Production

                        10.2.1.5 Development of Biosimilars Boosting the Demand for Preclinical Services

             10.2.2 Canada

                        10.2.2.1 Growing Stem Cell Research in Canada

                        10.2.2.2 Government Support for Development of Protein Drugs

     10.3 Europe 

             10.3.1 Launch of Pro-Test Deutschland in Germany

             10.3.2 Flourishing Biotechnology Industry in Germany

             10.3.3 Emphasis on Quality Research Results in the U.K.

             10.3.4 Increase in Cell Therapy Preclinical Research in the U.K.

             10.3.5 Funding for Rare Disease Projects in France

             10.3.6 Growth in Italy’s Biotech and Pharma Sector

             10.3.7 Growing Investments in Research By Sweden and Denmark

     10.4 Asia-Pacific 

             10.4.1 Strong Research Expenditure and Well-Structured Cro Industry in China

             10.4.2 Mandatory Animal Testing for All Pharmaceutical Drugs and Cosmetics in China

             10.4.3 Rising Focus on Personalized Medicine in China

             10.4.4 Increasing Investments From Government and Private Sectors in China’s Life Sciences Sector

             10.4.5 Government Support for Research, and Growth of Biomedical and Medical Research in Japan

             10.4.6 Research in Regenerative Medicine in Japan

             10.4.7 Growth of the Pharmaceutical Industry in India

             10.4.8 Development of Bio-Clusters to Boost India’s Biotechnology Sector

             10.4.9 Infrastructural Limitations in India: A Key Hindrance for Market Growth

             10.4.10 Ongoing Biomedical Research Activities in Australia

             10.4.11 Growth in Translational and Biomedical Research in Singapore

             10.4.12 Increase in Animal Research in Malaysia

             10.4.13 Rising Pharmaceutical and Biotechnology R&D Activities in Korea

     10.5 Rest of the World 

             10.5.1 Growth in the Pharmaceutical, Biotechnology, and Research Industries in Brazil

             10.5.2 Favorable Business Environment for Pharmaceutical and Biotechnology Industries in Saudi Arabia and the UAE

             10.5.3 Increasing Investments in Mexico

11 Competitive Landscape

     11.1 Overview 

     11.2 Market Share Analysis 

             11.2.1 Introduction

             11.2.2 Cell-Based Humanized Mouse Model Market

                        11.2.2.1 The Jackson Laboratory (U.S.)

                        11.2.2.2 Taconic Biosciences, Inc. (U.S.)

             11.2.3 Genetic Humanized Mouse Model Market

                        11.2.3.1 Horizon Discovery Group PLC (U.K.)

                        11.2.3.2 Taconic Biosciences, Inc. (U.S.)

     11.3 Competitive Situation and Trends 

     11.4 Agreements, Collaborations, Contracts, Alliances, and Partnerships 

     11.5 Grant/Fund 

     11.6 Product Launches 

     11.7 Expansions 

     11.8 Acquisitions 

     11.9 Other Strategies

12 Company Profiles

     12.1 Introduction 

     12.2 The Jackson Laboratory 

     12.3 Taconic Biosciences, Inc. 

     12.4 Horizon Discovery Group PLC 

     12.5 Genoway S.A. 

     12.6 Harbour Antibodies Bv (A Subsidiary of Harbour Biomed) 

     12.7 Humurine Technologies 

     12.8 Vitalstar Biotechnology Co., Ltd. 

     12.9 Ingenious Targeting Laboratory 

     12.10 Axenis S.A.S 

     12.11 Trans Genic, Inc. 

     12.12 Champions Oncology, Inc. 

     12.13 Crown Bioscience, Inc.

List of Tables (69 Tables) 

Table 1 Indicative List of Ongoing Clinical Trials Conducted on Humanized Mouse Models

Table 2 Indicative List of Research Studies Conducted on Humanized Mouse Models (2013–2016)

Table 3 Global Humanized Mouse Model Market Size, By Type, 2014–2021 (USD Million)

Table 4 Genetic Market Size, By Region, 2014–2021 (USD Million)

Table 5 Global Cell-Based Market Size, By Type, 2014–2021 (USD Million)

Table 6 Cell-Based Market Size, By Region, 2014–2021 (USD Million)

Table 7 North America: Cell-Based Humanized Mouse Model Market Size, By Country, 2014–2021 (USD Million)

Table 8 CD34 Market Size, By Region, 2014–2021 (USD Million)

Table 9 North America: CD34 Market Size, By Country, 2014–2021 (USD Million)

Table 10 PBMC Humanized Mouse Model Market Size, By Region, 2014–2021 (USD Million)

Table 11 North America: PBMC Market Size, By Country, 2014–2021 (USD Million)

Table 12 Recent Hiv Studies Using Humanized Mouse Model

Table 13 BLT Market Size, By Region, 2014–2021 (USD Thousand)

Table 14 North America: BLT Humanized Mouse Model Market Size, By Country, 2014–2021 (USD Thousand)

Table 15 Global Market, By Application, 2014–2021 (USD Million)

Table 16 Indicative List of Recent Cancer Research Studies Using Humanized Mouse Models

Table 17 Market for Oncology, By Region, 2014–2021 (USD Million)

Table 18 North America: Market Size for Oncology, By Country, 2014–2021 (USD Million)

Table 19 Humanized Mouse Model Market Size for Immunology and Infectious Diseases, By Region, 2014–2021 (USD Million)

Table 20 North America: Market Size for Immunology and Infectious Diseases, By Country, 2014–2021 (USD Million)

Table 21 Market Size for Neurosciences, By Region, 2014-2021 (USD Million)

Table 22 North America: Market Size for Neurosciences, By Country, 2014–2021 (USD Million)

Table 23 Humanized Mouse Model Market Size for Toxicology, By Region, 2014-2021 (USD Million)

Table 24 North America: Market Size for Toxicology, By Country, 2014–2021 (USD Million)

Table 25 Market Size for Hematopoiesis, By Region, 2014-2021 (USD Million)

Table 26 North America: Market Size for Hematopoiesis, By Country, 2014–2021 (USD Million)

Table 27 Humanized Mouse Model Market Size for Other Applications, By Region, 2014-2021 (USD Million)

Table 28 North America: Market Size for Other Applications, By Country, 2014–2021 (USD Million)

Table 29 Global Market, By End User, 2014–2021 (USD Million)

Table 30 Market Size for Pharmaceutical and Biotechnology Companies, By Region, 2014–2021 (USD Million)

Table 31 North America: Humanized Mouse Model Market Size for Pharmaceutical and Biotechnology Companies, By Country, 2014–2021 (USD Million)

Table 32 Market Size for Contract Research Organizations, By Region, 2014–2021 (USD Million)

Table 33 North America: Humanized Mouse Model Market Size for Contract Research Organizations, By Country, 2014–2021 (USD Million)

Table 34 Market Size for Academic and Research Institutions, By Region, 2014–2021 (USD Million)

Table 35 North America: Humanized Mouse Model Market Size for Academic and Research Institutions, By Country, 2014–2021 (USD Million)

Table 36 Market, By Region, 2014–2021 (USD Million)

Table 37 North America: Humanized Mouse Model Market, By Country, 2014–2021 (USD Million)

Table 38 North America: Market, By Type, 2014–2021 (USD Million)

Table 39 North America: Cell-Based Market Size, By Type, 2014–2021 (USD Million)

Table 40 North America: Humanized Mouse Model Market, By Application, 2014–2021 (USD Million)

Table 41 North America: Market, By End User, 2014–2021 (USD Million)

Table 42 NIH Funding for Projects Related to Animal Models

Table 43 Recent Events Related to the Animal Model Market

Table 44 U.S.: Humanized Mouse Model Market, By Type, 2014–2021 (USD Million)

Table 45 U.S.: Cell-Based Market Size, By Type, 2014–2021 (USD Million)

Table 46 U.S.: Market, By Application, 2014–2021 (USD Million)

Table 47 U.S.: Market, By End User, 2014–2021 (USD Million)

Table 48 Canada: Humanized Mouse Model Market, By Type, 2014–2021 (USD Million)

Table 49 Canada: Cell-Based Market Size, By Type, 2014–2021 (USD Thousand)

Table 50 Canada: Market, By Application, 2014–2021 (USD Thousand)

Table 51 Canada: Market, By End User, 2014–2021 (USD Million)

Table 52 Europe: Humanized Mouse Model Market, By Type, 2014–2021 (USD Million)

Table 53 Europe: Cell-Based Market Size, By Type, 2014–2021 (USD Million)

Table 54 Europe: Market, By Application, 2014–2021 (USD Million)

Table 55 Europe: Market, By End User, 2014–2021 (USD Million)

Table 56 Asia-Pacific: Humanized Mouse Model Market, By Type, 2014–2021 (USD Million)

Table 57 Asia-Pacific: Cell-Based Market Size, By Type, 2014–2021 (USD Thousand)

Table 58 Asia-Pacific: Humanized Mouse Model Market, By Application, 2014–2021 (USD Thousand)

Table 59 Asia-Pacific: Market, By End User, 2014–2021 (USD Million)

Table 60 RoW: Humanized Mouse Model Market, By Type, 2014–2021 (USD Million)

List of Figures (47 Figures) 

Figure 1 Global Humanized Mouse Model Market: Research Methodology

Figure 2 Sampling Frame: Primary Research

Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region

Figure 4 Market Size Estimation Methodology: Bottom-Up Approach

Figure 5 Market Size Estimation Methodology: Top-Down Approach

Figure 6 Research Design

Figure 7 Data Triangulation Methodology

Figure 8 Global Market, By Application (2016)

Figure 9 Global Market, By Type

Figure 10 Global Cell-Based Market, By Type

Figure 11 Global Market, By End User

Figure 12 Asia-Pacific to Witness Highest Growth During the Forecast Period

Figure 13 Increasing R&D Activities, Investments, and Grants to Drive Growth in the Global Market

Figure 14 North America to Dominate the Global Humanized Mouse Model Market in 2016

Figure 15 Oncology to Form the Largest Application Segment in the Global Market

Figure 16 Asia-Pacific to Register the Highest Market Growth From 2016 to 2021

Figure 17 Drivers, Restraints, Opportunities, and Challenges

Figure 18 U.S.: Clinical Trials Using Humanized Mouse Models, By Indication (2013–2023)

Figure 19 U.S.: Clinical Trials Using Humanized Mouse Models, By Completion

Figure 20 U.S.: Clinical Trials Using Humanized Mouse Models, By Phase (2013–2023)

Figure 21 U.S.: Research Studies Using Humanized Mouse Models, By Indication (2012–2016)

Figure 22 Genetic Humanized Mouse Model to Account for the Largest Market Share in 2016

Figure 23 CD34 Humanized Mouse Model to Grow at the Highest CAGR Between 2016 and 2021

Figure 24 Oncology Segment to Dominate the Humanized Mouse Model Market in 2016

Figure 25 Pharmaceutical and Biotechnology Companies to Dominate the Market in 2016

Figure 26 North America Dominates the Market for Humanized Mouse Models

Figure 27 North America: Humanized Mouse Model Market Snapshot

Figure 28 Europe: Market Snapshot

Figure 29 Increase in Cell Therapy Preclinical Studies in the U.K., 2013-2016

Figure 30 Asia-Pacific: Market Snapshot

Figure 31 Rest of the World: Market Snapshot

Figure 32 Key Developments in the Market, 2013–2016

Figure 33 Market Share Analysis for Cell-Based Humanized Mouse Model, By Key Player, 2015

Figure 34 Market Share Analysis for Genetic Humanized Mouse Model, By Key Player, 2015

Figure 35 Agreements, Collaborations, Contracts, Alliances, and Partnerships Was the Key Growth Strategy Adopted By Market Players

Figure 36 Agreements, Collaborations, Alliances, Contracts, and Partnerships, By Company (2013–2016)

Figure 37 Grant/Fund, By Company (2013–2016)

Figure 38 Product Launches, By Company (2013–2016)

Figure 39 Expansions, By Company (2013–2016)

Figure 40 Acquisitions, By Company (2013–2016)

Figure 41 Other Strategies, By Company (2013–2016)

Figure 42 Product Mix of the Top 3 Players in the Humanized Mouse Models Market

Figure 43 The Jackson Laboratory: Company Snapshot (2015)

Figure 44 Horizon Discovery Group PLC: Company Snapshot (2015)

Figure 45 Genoway S.A.: Company Snapshot (2015)

Figure 46 Trans Genic, Inc.: Company Snapshot (2015)

Figure 47 Champions Oncology, Inc.: Company Snapshot (2015)